Role of Drug Metabolism in Drug Development

Drug Metabolism in Drug Design and Development: Basic Concepts and Practice

Volumn , Issue , 2007, Pages 261-285

  Iyer, Ramaswamy ^a   Zhang, Donglu ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug drug interaction; Genetic polymorphisms and drug metabolizing enzymes; Human liver microsomes and hepatocytes

Indexed keywords

EID: 75749134257     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470191699.ch9     Document Type: Chapter

References (62)

1. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002;72:685-691.
2. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, Shipley LA. Drug metabolites in safety testing. Toxicol Appl Pharmacol 2002;182:188-196.
3. Baillie TA, Kassahun K. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Adv Exp Med Biol 2001;500:45-51.
4. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-469.
5. Cohen LH, Remley MJ, Raunig D, Vaz AD. In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.
6. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla C, Huang SM, Lesko LJ. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999;39:899-910.
7. de Graaf IAM, van Meijeren CE, Pektas F, Koster HJ. Comparison of in vitro preparations for semiquantitative prediction of in vivo drug metabolism. Drug Metab Dispos 2002;30:1129-1136. DOI:10.1124/dmd.30.10.1129.
8. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
9. Ekins S, Williams JA, Murray GI, Burke MD, Marchant NC, Engeset J, Hawksworth GM. Xenobiotic metabolism in rat, dog, and human precision-cut liver slices, freshly isolated hepatocytes, and vitrified precision-cut liver slices. Drug Metab Dispos 1996;24:990-995.
10. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004;17:3-16.
11. Fennell TR, Kedderis GL, Sumner SCJ. Urinary metabolites of [1,2,3-13C]acrylonitrile in rats and mice detected by 13C nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1991;4:678-687.
12. Fennell TR, Sumner SCJ. Identification of metabolites of carcinogens by 13C NMR spectroscopy. Drug Metab Rev 1994;26:469-481.
13. Ghibellini G, Leslie EM, Brouwer KL. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharmacol 2006;3:198-211.
14. Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, Zbaida S. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes. Biopharm Drug Dispos 2003;24:375-384.
15. Gomez-Lechon MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 2003;4:292-312.
16. Greenblatt DJ, von Moltke LL. Drug-drug interactions: clinical perspective. In:Rodrigues AD, editor. Drug-Drug Interactions. New York: Marcel Dekker; 2002. p 565-584.
17. Hall EJ. Radiobiology for the Radiologist. JB Lippincott Company; 1994.
18. Hewitt NJ, Utesch D. Cryopreserved rat, dog and monkey hepatocytes: measurement of drug metabolizing enzymes in suspensions and cultures. Hum Exp Toxicol 2004;23:307-316.
19. Huang SM, Lesko LJ. Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 2004;44:559-569.
20. Iyer RA, Malhotra B, Sanaullah K, Mitroka J, Bonacorsi SJ, Waller SC, Rinehart JK, Kripalani K. Comparative biotransformation of radiolabeled [14C]omapatrilat and stable-labeled [13C2]omapatrilat after oral administration to rats, dogs, and humans. Drug Metab Dispos 2003;31:67-75.
21. Iyer RA, Mitroka J, Malhotra B, Bonacorsi SJ, Waller SC, Rinehart JK, Roongta VA, Kripalani K. Metabolism of [14C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans. Drug Metab Dispos 2001;29:60-69.
22. Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005;77:404-414.
23. Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development. Med Res Rev 2001;21:397-411.
24. Lilja JJ, Backman JT, Neuvonen PJ. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:433-439.
25. Lu AY, Wang RW, Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 2003;31:345-350.
26. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs:correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002;30:795-804.
27. Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics:biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 2004;5:483-505.
28. Marathe PH, Shyu WC, Humphreys WG. The use of radiolabeled compounds for ADME studies in discovery and exploratory development. Curr Pharm Des 2004;10:2991-3008.
29. Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002;302:369-373.
30. Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A, Grossi P. Phase I and phase II metabolic activities are retained in liver slices from mouse, rat, dog, monkey and human after cryopreservation. Toxicol In Vitro 2004;18:121-128.
31. McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 2004;32:1247-1253.
32. Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH, Shou M. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. J Pharmacol Exp Ther 1999;291:749-759.
33. Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 1999;27:1319-1333.
34. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000;169:102-113.
35. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003a;46:1319-1323.
36. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003b;46:347-351.
37. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolismdependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006;34:191-197.
38. Parker RJ, Hirom PC, Millburn P. Enterohepatic recycling of phenolphthalein, morphine, lysergic acid diethylamide (LSD) and diphenylacetic acid in the rat. Hydrolysis of glucuronic acid conjugates in the gut lumen. Xenobiotica 1980;10:689-703.
39. Parkinson A. Biotransformation of xenobiotics. In: Klassen CD, editor. Casarett & Doull's Toxicology: The Basic Science of Poisons McGraw-Hill; 2001. p 133-224.
40. Product Note for guidance on the investigation of drug interactions (CPMP/EWP/560/95). Available atwww.eudra.org/humandocs/humans/EWP.html.
41. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999;57:465-480.
42. Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 2004;311:228-236.
43. Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, Rodrigues AD. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 2006;7:375-388.
44. Solon EG, Balani SK, Lee FW. Whole-body autoradiography in drug discovery. Curr Drug Metab 2002;3:451-462.
45. Solon EG, Kraus L. Quantitative whole-body autoradiography in the pharmaceutical industry. Survey results on study design, methods, and regulatory compliance. J Pharmacol Toxicol Methods 2001;46:73-81.
46. Sumner SCJ, Stedman DB, Clarke DO, Welsch F, Fennell TR. Characterization of urinary metabolites from [1,2,methoxy-13C]-2-methoxyethanol in mice using 13C nuclear magnetic resonance spectroscopy. Chem Res Toxicol 1992;5:553-560.
47. US Food and Drug Administration Guidance for industry: drug metabolism/drug interaction studies in the drug development process: studies in vitro. Available at www.fda.gov/cder/guidance.html.
48. Valentin J. Basic anatomical and physiological data for use in radiological protection:reference values: ICRP Publication 89. Annals of the ICRP 2002;32:1-277.
49. Wait JCM, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, Iyer RA. Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans. Drug Metab Dispos 2006;34:961-970.
50. Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, Humphreys WG. Glucuronidation as a major metabolic clearance pathway of 14C-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. Drug Metab Dispos 2006;34:427-439. Epub 2005 Dec 20-28.
51. Wen X, Wang J-S, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29:1359-1361.
52. WHO.Use of ionizing radiation and radionuclides on human beings for medical research, training and nonmedical purpose. WHO Publication 611;1977.
53. Williams JA, Hurst SI, Bauman J, Jones BC, Hyland R, Gibbs JP, Obach RS, Ball SE. Reaction phenotyping in drug discovery: moving forward with confidence? Curr Drug Metab 2003;4:527-534.
54. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 2004;32:1201-1208.
55. Yamamoto T, Suzuki A, Kohno Y. Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns. Drug Metab Pharmacokinet 2002;17:437-448.
56. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005;33:1729-1739.
57. Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H, Davis CD, Humphreys WG. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos 2007;35:139-149.
58. Zhang D, Raghavan N, Chando T, Gambardella J, Fu Y, Zhang DX, Unger S, Humphreys WG. LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials by using radioactive metabolites as reference standards. Drug Metab Lett 2007a; in print.
59. Zhang H, Zhang D, Ray K. A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analysis. J Mass Spectrom 2003;38:1110-1112.
60. Zhang ZY, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr Drug Metab 2005;6:241-257.
61. Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A.Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 2004;5:415-442.
62. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304.